Clinical trial
Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic…
NCT00479622 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00479622 |
|---|---|
| Title | Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus |
| Official title | A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Collaborators | Emergent Product Development Seattle LLC Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | TRU-015 |
| Enrollment | 20 |
| Start date | Aug 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 28, 2007 |
| Last update posted | May 8, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: